BK Treatment Study

BK Viremia Clinical Trial

Official title:
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study

Status Completed

Clinical Trial Summary

Our hypothesis is that 30 days of oral levofloxacin (FDA approved antibiotic) in patients with persistent viremia (BK virus found in blood) will impair progress to BK virus induced kidney damage by significantly decreasing or eliminating BK virus in the blood.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01034176
Study type	Interventional
Source	Brigham and Women's Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	February 2009
Completion date	October 2012

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05224583` - Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant
Completed	`NCT01649609` - Using mTOR Inhibitors in the Prevention of BK Nephropathy	N/A
Recruiting	`NCT05325008` - A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients	Phase 3